Company: XOMAP
Filing Date: 2025-09-17
Form Type: SC TO-T/A
Source: 0001193125-25-205563
Chunk: 2

Company: XOMA Royalty Corp
Filing Date: 2025-09-17
Form: SC TO-T/A
Chunk 2
---
 such terms in the Schedule TO and the Offer to Purchase.

ITEMS 1 THROUGH 9 AND 11

Items 1 through 9 and 11 of the Schedule TO, to the extent such Items incorporate by reference the information contained in the Offer to
Purchase, are hereby amended and supplemented as follows:

“Closing of the Merger

The Offer expired as scheduled, one minute past 11:59 p.m. Eastern Time on September 15, 2025 (the “”)
and was not extended. The Depositary and Paying Agent has advised Purchasers that, as of the Expiration Date, a total of 39,214,689 Shares were validly tendered into, and not validly withdrawn from, the Offer, representing approximately 77.48% of
Shares that were issued and outstanding as of the Expiration Date. All conditions to the Offer, including the Minimum Tender Condition, having been satisfied or waived, Purchasers irrevocably accepted for payment, and made payment for all Shares
validly tendered and not validly withdrawn in the Offer.

On September 17, 2025, Purchasers completed the acquisition of HilleVax pursuant
to the terms of the Merger Agreement through the merger of Merger Sub with and into HilleVax in accordance with Section 251(h) of the DGCL, with HilleVax continuing as the surviving corporation in the Merger and thereby becoming a wholly owned
subsidiary of Parent. At the Effective Time, each issued and outstanding Share not tendered into the Offer (other than any Shares (A) owned by HilleVax immediately prior to the Effective Time, (B) owned by Merger Sub, Parent or any other
subsidiary of Parent at the commencement of the Offer and by Parent, Merger Sub or any other subsidiary of Parent immediately prior to the Effective Time, (C) irrevocably accepted for purchase in the Offer or (D) held by any stockholders
or owned by any beneficial owners of capital stock of HilleVax who are entitled to and who properly exercise appraisal rights under Delaware law) was automatically converted into the right to receive the Offer Price.

The Shares ceased to trade on Nasdaq prior to the commencement of trading on September 17, 2025, and HilleVax has requested that Nasdaq file a
Notification of Removal from Listing and/or Registration under Section 12(b) of the Exchange Act on Form 25 to delist